OPKO Health, Inc. (OPK)
NASDAQ: OPK · Real-Time Price · USD
1.375
-0.015 (-1.08%)
Nov 5, 2025, 1:23 PM EST - Market open
OPKO Health Revenue
OPKO Health had revenue of $151.67M in the quarter ending September 30, 2025, a decrease of -12.65%. This brings the company's revenue in the last twelve months to $642.07M, down -9.75% year-over-year. In the year 2024, OPKO Health had annual revenue of $713.14M, down -17.41%.
Revenue (ttm)
$642.07M
Revenue Growth
-9.75%
P/S Ratio
1.58
Revenue / Employee
$214,237
Employees
2,997
Market Cap
1.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 713.14M | -150.35M | -17.41% |
| Dec 31, 2023 | 863.50M | -140.70M | -14.01% |
| Dec 31, 2022 | 1.00B | -770.52M | -43.42% |
| Dec 31, 2021 | 1.77B | 339.31M | 23.64% |
| Dec 31, 2020 | 1.44B | 533.48M | 59.15% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
OPK News
- 6 days ago - OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 13 days ago - OPKO Health to Report Third Quarter 2025 Financial Results on October 29 - GlobeNewsWire
- 7 weeks ago - Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses - PRNewsWire
- 3 months ago - OPKO Health, Inc. (OPK) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 4 months ago - NextPlat Issues Interim CEO Update Shareholder Letter - PRNewsWire
- 4 months ago - OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium - GlobeNewsWire